相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。
Article
Medicine, General & Internal
Peter Nordstrom et al.
Summary: This study investigated the effectiveness of COVID-19 vaccines against infection, hospitalization, and death in the Swedish population during the first 9 months after vaccination. The findings suggest that vaccine effectiveness decreases over time, but the rate of waning varies by vaccine type. The effectiveness in preventing severe COVID-19 seems to be better maintained. The results provide support for administering a third vaccine dose as a booster.
Editorial Material
Infectious Diseases
Noah Kojima et al.
LANCET INFECTIOUS DISEASES
(2022)
Editorial Material
Medicine, General & Internal
Halane Vaillant-Roussel et al.
EXERCER-LA REVUE FRANCOPHONE DE MEDECINE GENERALE
(2022)
Review
Medicine, General & Internal
Daniel R. Feikin et al.
Summary: This study systematically reviewed the duration of protection provided by COVID-19 vaccines against various clinical outcomes. The findings indicate that the effectiveness or efficacy of the vaccines decreased from 1 to 6 months after full vaccination, but remained high against severe disease. Evaluating the effectiveness or efficacy of vaccines beyond 6 months is crucial for updating vaccine policies.
Article
Medicine, General & Internal
Merryn Voysey et al.
Summary: The ChAdOx1 nCoV-19 vaccine has been shown to have an acceptable safety profile and effectiveness against symptomatic COVID-19, with higher efficacy observed in the group that received a low dose followed by a standard dose.
Article
Medicine, General & Internal
Laith J. Abu-Raddad et al.
Summary: This study aimed to assess the protection against breakthrough infection with SARS-CoV-2 after mRNA vaccination, comparing individuals with and without prior infection. The findings showed that individuals with prior SARS-CoV-2 infection had a significantly lower risk for breakthrough infection, indicating a potential benefit of natural immunity in vaccine protection.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2021)
Article
Public, Environmental & Occupational Health
Jonathan Bergman et al.
Summary: This nationwide study in Sweden identified age, sex, and comorbidity as major risk factors for severe COVID-19. Additionally, hypertension, asthma, Down syndrome, and residence in a long-term care facility were associated with severe COVID-19.
EUROPEAN JOURNAL OF EPIDEMIOLOGY
(2021)
Article
Medicine, General & Internal
Ann R. Falsey et al.
Summary: The clinical trial in the United States, Chile, and Peru showed that the AZD1222 vaccine was both safe and effective in preventing symptomatic and severe Covid-19 cases, with an overall estimated efficacy of 74% and a higher efficacy of 83.5% in participants 65 years of age or older. The high vaccine efficacy was consistent across various demographic subgroups, and antibodies increased significantly after each dose.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Letter
Medicine, General & Internal
Hiam Chemaitelly et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Multidisciplinary Sciences
Rishi R. Goel et al.
Summary: This study found that immune memory to SARS-CoV-2 and its variants remains robust for at least 6 months after mRNA vaccination, with antibodies declining but still detectable in most individuals. mRNA vaccines also induced functional memory B cells and antigen-specific T cells, with recall responses primarily increasing antibody levels in individuals with preexisting immunity.
Article
Multidisciplinary Sciences
Jia Wei et al.
Summary: Understanding antibody responses after SARS-CoV-2 infection is crucial for assessing protection and risk of reinfection. This study, using representative data from the UK, found that 24% of participants did not develop anti-spike antibodies, with older participants and those of non-white ethnicity having higher peak antibody levels. The estimated antibody levels associated with protection against reinfection may last 1.5-2 years on average.
NATURE COMMUNICATIONS
(2021)
Article
Medicine, General & Internal
Christian Holm Hansen et al.
Summary: The study investigated the protection against SARS-CoV-2 reinfection, with results showing an 80.5% protection rate for individuals previously infected. Even in the population aged 65 years and older, the protection rate against reinfection reached 47.1%, with no significant differences observed by gender or time since infection.
Article
Medicine, General & Internal
Eric J. Haas et al.
Summary: This study assessed the real-world effectiveness of the Pfizer-BioNTech mRNA COVID-19 vaccine BNT162b2 in Israel, showing high efficacy in preventing SARS-CoV-2 infections, hospitalizations, severe disease, and death. As vaccine coverage increased, there were marked declines in SARS-CoV-2 outcomes, indicating that COVID-19 vaccination can help control the pandemic.
Article
Geriatrics & Gerontology
Marcel Ballin et al.
Summary: This retrospective cohort study aimed to compare the 30-day mortality in LTCF residents with and without COVID-19, and investigate the impact of various risk factors on mortality in COVID-19 cases. The study found a significantly higher mortality rate in COVID-19 cases compared to controls, with factors like older age, male sex, and neuropsychological conditions contributing to higher mortality rates in COVID-19 patients.
JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION
(2021)
Letter
Geriatrics & Gerontology
Marek Petras
JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION
(2021)
Article
Infectious Diseases
Catherine Hyams et al.
Summary: The study found that one dose of either the BNT162b2 or ChAdOx1 nCoV-19 vaccines resulted in substantial risk reductions for COVID-19-related hospitalisations in those aged over 80 years.
LANCET INFECTIOUS DISEASES
(2021)
Article
Biochemistry & Molecular Biology
Hiam Chemaitelly et al.
Summary: A study showed that the mRNA-1273 vaccine is highly effective against the B.1.1.7 and B.1.351 variants of concern, with efficacy rates of 100% and 96.4% respectively. The vaccine's effectiveness increases rapidly in the weeks following the first dose, reaching maximum efficacy after the second dose, providing strong protection against severe COVID-19 outcomes.
Article
Medicine, General & Internal
H. M. El Sahly et al.
Summary: The mRNA-1273 vaccine demonstrated high efficacy in preventing COVID-19 illness and severe disease, with more than 5 months of protection and a good safety profile, including protection against asymptomatic infection.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Medicine, General & Internal
S. J. Thomas et al.
Summary: BNT162b2 vaccine remains highly effective and safe over the course of 6 months post-vaccination, with efficacy rates ranging from 86% to 100% across different demographics and risk factors for Covid-19. The vaccine also shows a high efficacy against severe disease, with particularly promising results observed in South Africa against the B.1.351 variant.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
